secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001193125-23-168118
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan shareholders approve 7.5M share increase to 2021 equity plan; options granted to executives
--------------------------------------------------------------------------------

- Stockholders approved Plan Amendment increasing authorized shares by 7,500,000 to 10,778,048 at June 13 annual meeting.
- CEO Gavin MacBeath granted options for 1,121,300 shares at $2.49; CFO Brian Silver granted 632,500 shares at $2.49, contingent on amendment approval.
- Non-employee director option grants increased to 35,000 shares per director annually, vesting at earlier of one year or next annual meeting.
- Board committee changes: Barbara Klencke joins Audit and Compensation; Gabriela Gruia joins Audit and Nominating; Timothy Barberich steps down from all committees.
- Stockholders also elected Katina Dorton as Class II director and ratified Deloitte & Touche as independent auditor for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523168118/0001193125-23-168118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523168118/d522944d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-168118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer